bisphosphonates


Also found in: Dictionary.

bis·phos·pho·nates

(bis-fos'fō-nāts),
Synthetic pyrophosphate analogues that inhibit osteoclast resorption of bone.

bis·phos·pho·nates

(bis-fos'fŏ-nāts)
Class of medications to treat osteoporosis.

bisphosphonates

A class of drugs that resemble pyrophosphate but are not readily hydrolysed. They interfere with the action of OSTEOCLASTS and thus prevent bone reabsorption in conditions such as PAGET'S DISEASE and OSTEOPOROSIS. They have an established place in the management of metastatic bone secondaries in cancer. The class includes drugs such as clodronate and etidronate (with no nitrogen moiety attached to the central carbon atom side chain), and pamidronate, alendronate, risendronate, ibandronic acid and zoledronic acid, with the nitrogen moiety. The latter group are more potent inhibitors of bone resorption but have more side effects.

bisphosphonates

therapeutic agents (e.g. alendronic acid [Fosamax], disodium etidronate [Didronel] and risedronate [Actonel]) used to prevent and treat osteoporosis, osteogenesis imperfecta and Paget's disease

bisphosphonates

calcium-regulating drugs which inhibit bone resorption; used in the treatment of hypercalcemia and osteoporosis in humans. Previously called diphosphonates and biphosphonates.
References in periodicals archive ?
But this process begins with resorption--and if resorption is slowed by bisphosphonates, the remodeling process is affected.
In addition to the promising signal of a preventive effect for bisphosphonates, her analysis of Osteoarthritis Initiative data yielded two other major findings: Changes over time in the MRI-based three-dimensional bone shape of the knee constitute a novel structural imaging biomarker that appears to be of value in monitoring patients with OA or at high risk for the joint disease, and bisphosphonate-induced suppression of bone turnover had no adverse long-term impact on osteoarthritis risk.
Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.
The guidelines emphasize the need for reassessment of fracture risks on a regular basis for all women being treated with bisphosphonates for osteoporosis.
BRONJ is the most seen complication (66%) due to bisphosphonates usage.
Bisphosphonates build up in the bone, so if you stop taking the medication after a period of time, its positive effect should persist.
The second hip fracture incidence, mortality and complications were compared between bisphosphonates and control groups.
UCB today announced detailed Phase 3 results showing the investigational agent romosozumab demonstrated a statistically significant increase in hip bone mineral density (BMD) and strength compared with teriparatide in postmenopausal women with osteoporosis transitioning from bisphosphonate treatment.
Given the effective metal-complexing behavior of bisphosphonates, some synergistic effects of bisphosphonates and metal complexes maybe expected.
Laboratory blood tests including serum calcium, phosphate, alkaline phosphatase, vitamin D, thyroid, and parathyroid hormone levels were all normal to evaluate whether to use bisphosphonates after bone healing.
Bisphosphonates are prescribed as the first choice treatment in patients with osteoporosis and they strongly inhibit bone resorption.
In addition, expanded bisphosphonate use could cause nearly 20,000 more atypical femur fractures in this population, Dr.